John Charles Thomas Sells 642 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Trading Up 1.2%

KRYS stock opened at $310.30 on Friday. Krystal Biotech, Inc. has a 1-year low of $123.03 and a 1-year high of $319.48. The firm has a market cap of $9.15 billion, a P/E ratio of 41.48 and a beta of 0.50. The business’s 50 day moving average is $276.42 and its 200-day moving average is $260.43.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Sell-side analysts forecast that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Analyst Ratings Changes

KRYS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $310.00 price objective on shares of Krystal Biotech in a research note on Monday, May 18th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Citigroup increased their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Chardan Capital increased their price target on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $324.11.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the business. Bessemer Group Inc. lifted its holdings in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after buying an additional 77 shares in the last quarter. Sound Income Strategies LLC boosted its position in Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after buying an additional 127 shares during the last quarter. Western Wealth Management LLC bought a new position in Krystal Biotech in the 1st quarter valued at $34,000. Greenline Wealth Management LLC bought a new position in Krystal Biotech in the 4th quarter valued at $34,000. Finally, Danske Bank A S bought a new position in Krystal Biotech in the 3rd quarter valued at $35,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.